STOCK TITAN
  1. Home
  2. News
  3. VNRX

VolitionRX Limited - VNRX STOCK NEWS

Welcome to our dedicated page for VolitionRX news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRX stock.

VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.

The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.

VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.

In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.

VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.

For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.

News

Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech

Rhea-AI Summary
VolitionRx launches Nu.Q® Vet Cancer Test in-clinic in U.S. and Europe through Antech, providing rapid, accurate, and cost-effective cancer screening for high-risk breeds and older dogs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.67%
Tags
none
-
News

VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update

Rhea-AI Summary
VolitionRx (VNRX) reports a successful fiscal year 2023 with significant financial growth and strategic partnerships. The company's Nu.Q® Vet Cancer Test gained traction in the companion animal healthcare sector, resulting in substantial sales and collaborations. Volition also made progress in its Nu.Q® NETs pillar and introduced a groundbreaking cancer detection method, Capture-PCR™. Financially, the company saw a notable increase in revenue, received substantial milestone payments, and maintained a healthy cash position. Volition's management remains optimistic about future milestones and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
earnings
-
News

VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update

Rhea-AI Summary
VolitionRx (VNRX) to host conference call to discuss Q4 and full year 2023 financial results and business update on March 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.75%
Tags
earnings
News

Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan

Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) partners with Fujifilm Vet Systems to supply Nu.Q® Vet Cancer Test in Japan, enhancing early cancer detection for dogs. The accessible test aims to improve patient care through early intervention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none
-
News

Volition appoints Dr Andrew Retter as Chief Medical Officer

Rhea-AI Summary
VolitionRx appoints Dr. Andrew Retter as Chief Medical Officer to lead medical efforts aligned with patient needs. Dr. Retter brings expertise in Intensive Care Medicine and Haematology, enhancing Volition's focus on cutting-edge diagnostic solutions for early disease detection and treatment monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
management
-
News

Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar

Rhea-AI Summary
VolitionRx Limited (NYSE American: VNRX) is participating in a webinar hosted by Edison Group to update stakeholders on recent developments and ongoing studies for its Nu.Q® NETs test. The webinar will include updates from Volition's Chief Commercial Officer and a leading UK-based Intensive Care Consultant. The event aims to provide an understanding of sepsis, highlight the challenges in diagnosing, treating, and monitoring the disease, and outline Volition's next steps towards commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
News

Volition Issues Business Review 2023

Rhea-AI Summary
VolitionRx Limited (VNRX) Issues Business Review of 2023, Highlighting Key Achievements
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.1%
Tags
none
-
News

VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre

Rhea-AI Summary
VolitionRx Limited (VNRX) secures Euro 5.0 million financing from Wallonie Entreprendre S.A. for the ongoing development of its Nu.Q® product portfolio, including clinical and regulatory programs for Nu.Q® NETs, aiming to aid in the early diagnosis of diseases such as sepsis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
News

Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society

Rhea-AI Summary
VolitionRx Limited (NYSE AMERICAN: VNRX) is presenting at the 5th Annual Congress of Liquid Biopsy in Madrid, Spain. The company's Chief Scientific Officer, Dr. Jake Micallef, will present a session on 'An Introduction to circulating nucleoproteins.' Volition recently unveiled a new cancer detection method generating significant interest from diagnostic and liquid biopsy companies. The method involves the physical isolation of tumor-derived ctDNA fragments from blood, allowing for the detection of a range of liquid and other cancers, including at early stages, with high specificity using a simple, low-cost PCR test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
News

VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update

Rhea-AI Summary
VolitionRx Limited (VNRX) Announces Strong Financial Results in Q3 2023 and Business Update. The company reported a significant revenue growth of 185% year-over-year and made notable progress with its Nu.Q® NETs pillar, securing FDA agreement and presenting new data at ESICM congress. The company's innovative cancer detection method unveiled at ESMO 2023 received positive feedback, and they are expanding their Nu.Q® Vet Cancer Test globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
earnings

FAQ

What is the current stock price of VolitionRX (VNRX)?

The current stock price of VolitionRX (VNRX) is $0.6759 as of December 20, 2024.

What is the market cap of VolitionRX (VNRX)?

The market cap of VolitionRX (VNRX) is approximately 56.5M.

What does VolitionRx Limited do?

VolitionRx Limited develops non-invasive blood tests for early detection and monitoring of diseases, including cancers, using their proprietary Nucleosomics™ platform.

Where is VolitionRx Limited based?

VolitionRx Limited is a U.S.-based company with research and development activities centered in Belgium. They also have offices in the U.S., London, and Singapore.

What is the Nu.Q® Vet Cancer Test?

The Nu.Q® Vet Cancer Test is a blood test developed by VolitionRx to aid early cancer detection in dogs. It's available through partnerships with Fujifilm Vet Systems in Japan and Antech Diagnostics in the U.S. and Europe.

What are VolitionRx's recent achievements?

In 2023, VolitionRx expanded its partnership network, commercialized its veterinary products, and advanced its human diagnostics pipeline with plans for regulatory submissions and new clinical studies.

What is the Nucleosomics™ platform?

Nucleosomics™ is VolitionRx's proprietary technology for identifying and measuring nucleosomes in the bloodstream, which can indicate the presence of disease.

How is VolitionRx planning to achieve cash flow neutrality by 2025?

VolitionRx aims for cash flow neutrality by 2025 through revenue growth, milestone payments from licensing agreements, and cost reduction measures.

How can I get more information about VolitionRx?

Visit their website at www.volitionrx.com or follow them on Twitter, LinkedIn, and Facebook for the latest updates and information.

What diseases does VolitionRx target with its tests?

VolitionRx targets a range of diseases, including various cancers and diseases associated with NETosis, such as sepsis and COVID-19.

What is the significance of VolitionRx's partnership with Fujifilm Vet Systems?

The partnership allows Fujifilm Vet Systems to sell and perform cancer screening services for dogs using the Nu.Q® Vet Cancer Test throughout Japan, enhancing early cancer detection.

What upcoming milestones does VolitionRx expect?

VolitionRx anticipates publishing new data for their Nu.Q® NETs and Capture-PCR™ technologies and advancing their regulatory pathways in 2024.

Stock VNRX logo
VolitionRX Limited

NYSE:VNRX

VNRX Rankings

#4793 Ranked by Market Cap
N/A Ranked by Dividends

VNRX Stock Data

56.49M
70.00M
22.82%
19.11%
0.48%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
HENDERSON